New Alzheimer’s Vaccine May Show Promise.

September 4, 2019 | 239 views

Many biotechs have aimed to resolve Alzheimer’s via a vaccine over recent years, only to call it off due to nasty side effects such as brain swelling. But this drug, which the company has dubbed UB-311, is offering hope after wrapping up a Phase 2a Clinical Study. Next, the drug will begin a 2b study, which will further determine efficacy, before going on to a Phase 3 study if all is successful. Phase 3 is the necessary trial before drug approval and is tested on large groups of patients.

Spotlight

Aveva Drug Delivery Systems

AVEVA is a global leader in transdermal drug delivery located in the United States. The company has an extensive history of providing pharmaceutical partners with fully integrated, controlled-release transdermal products that fulfill unmet market needs or supply high-quality, affordable brand equivalents.

OTHER ARTICLES
PHARMA TECH

Tips for Managing Chronic Pain Beyond Prescription Painkillers

Article | July 15, 2022

Painkillers like Oxycontin, Percocet, and Vicodin, have been prescribed by primary physicians, surgeons, dentists, and other healthcare providers to patients suffering from varying levels of pain. Though these medications have proven to be an effective source of pain relief, they have also proven to be highly addictive. In fact, it has even been reported that there are more cases of a drug overdose and deaths from prescription painkillers than heroin or cocaine. While there are a number of factors that play into this opioid epidemic, educating doctors and patients on alternative solutions to managing chronic pain is a great place to start combatting this nationwide crisis.

Read More
PHARMA TECH

What are the advantages of PCD Pharma Company?

Article | September 29, 2022

PCD Pharma stands for propaganda distribution. A PCD company gives brand name and support to its franchises. They also provide distribution rights and monopoly rights within a particular region. If a person wants to establish their business, it is a must for them to know the pros and cons of the business to make a sound decision. Needless to mention that PCD company has a lot to contribute in the medical filed. Worldwide in a medical field, A PCD Pharma Company is playing an essential and crucial role in the rapid growth. The pharma industry is progressing t a fast pace. The company uses the latest technologies for each brand which ensures the safety of products and accepts the responsibility of human health & life by providing better outcomes. To have a drug license number and company registration, the cost to establish the company is quite cost-effective that is15000-20000rs. So this gives people a brilliant opportunity to have their unit without digging a big hole in their bank balance. Indian produces exquisite quality products, which make pharma companies a considerable success.

Read More
PHARMA TECH

WALGREEN’S IN HOT WATER OVER PHONY PHARMACIST

Article | July 12, 2022

The drugstore chain agreed to pay $7.5 million in fines after an unlicensed pharmacist at several San Francisco Bay locations illegally filled more than 700,000 prescriptions over a ten-year period. According to California prosecutors, Kim Thien Le stole license numbers from other pharmacists to fill prescriptions for Fentanyl, morphine, and other painkillers. Le pleaded guilty to multiple felony impersonation counts. Walgreen’s agreed to the settlement to avoid being charged with consumer fraud in Alameda and Santa Anna Counties. Prosecutors alleged that Walgreen’s failed to verify Le’s license and did not conduct a thorough background check. The company insisted it has taken remedial measures.

Read More

How Can Medical Cannabis Help to Manage Pain Conditions? – The Cannabis Exchange

Article | February 11, 2020

Pain management is one of the most common reasons for the use of medical cannabis products. However, despite many jurisdictions – including Canada, Germany, and the Netherlands – now allowing the prescription of medical cannabis for this purpose, there remains little ‘high-quality’ evidence to support, or oppose its efficacy. Madden et al. (2018) set out to review the evidence available in order to determine the efficacy of medical cannabis when employed in the management of various forms of musculoskeletal pain. The researchers analysed various studies that assessed the use of cannabinoids in the treatment of arthritis pain; back pain; postoperative pain; and trauma-related pain. It is estimated that up to 30% of the population may suffer from a non-cancer-related pain condition. As such a high percentage of people suffer from these conditions, the development of simple and safe therapies is an essential area of research. This is particularly important as the therapeutic options for people with chronic pain are increasingly limited.

Read More

Spotlight

Aveva Drug Delivery Systems

AVEVA is a global leader in transdermal drug delivery located in the United States. The company has an extensive history of providing pharmaceutical partners with fully integrated, controlled-release transdermal products that fulfill unmet market needs or supply high-quality, affordable brand equivalents.

Related News

Vaccine for Lassa Fever Set To Be Trialed

Technology Networks | October 25, 2019

There is currently no vaccine for the Lassa arenavirus, which causes Lassa fever. This hemorrhagic fever, endemic in West Africa, infects up to 300,000 people each year. Given the urgency of the situation, scientists in the Biology of Viral Emerging Infections Unit and the Viral Genomics and Vaccination Unit at the Institut Pasteur evaluated the efficacy of several vaccine candidates. Following their analyses, they identified one of these vaccines, based on the measles platform, as being the most effective to enter clinical testing in humans as soon as possible. This raises hopes in the fight against a disease that claims between 5,000 and 6,000 lives every year. Lassa fever, a hemorrhagic fever caused by the Lassa virus (LASV), is responsible for several thousands of deaths in endemic countries in West Africa every year. The natural reservoir of the virus is a peridomestic rodent that lives near or inside homes, so contacts between humans and the infected reservoir in villages are frequent (see our disease fact sheet). Humans are generally infected by ingesting or inhaling material contaminated with the animal's excreta (urine or feces). Early diagnosis of Lassa fever is difficult to establish because the first symptoms are non-specific (fever, vomiting and nausea), and there is currently no treatment. Vaccinating the populations concerned is therefore the most promising strategy to deal with recurrent outbreaks of Lassa fever. The World Health Organization (WHO) has included Lassa fever in its R&D Blueprint list of epidemic threats needing urgent R&D action. Frédéric Tangy, Head of the Institut Pasteur's Viral Genomics and Vaccination Unit, said in an interview: "When it comes to vaccines, all the easy work has already been done, and the more difficult work has still not been completed. Fundamental research is vital for the development of new solutions."

Read More

Lipid nanoparticles used to deliver RNA in vaccines

European Pharmaceutical Review | September 30, 2019

Researchers have developed a series of lipid nanoparticles, which encapsulate RNA, for effective and improved vaccine delivery. Researchers have developed a series of lipid nanoparticles to deliver RNA vaccines accurately, to ensure the therapy reaches the correct immune cells and produces sufficient amounts of the encoded protein. A team from the Massachusetts Institute of Technology (MIT), US conducted the research into the vaccine. They say it also behaves like an “adjuvant”, boosting the effectiveness of the treatment. Using mouse models, the researchers showed that the RNA vaccine is successful in inhibiting the growth of melanoma tumours. “One of the key discoveries of this paper is that you can build RNA delivery lipids that can also activate the immune system in important ways,” says Daniel Anderson, an associate professor at MIT and the senior author of the study. Anderson’s lab has previously developed lipid nanoparticles for delivering RNA and DNA for a variety of applications. These lipid particles form tiny droplets that protect the RNA molecules and carry them to their destinations.

Read More

Vaccines for Alzheimer’s: exploiting similarities with Down syndrome

Pharmaceutical Technology | September 20, 2019

One approach to overcome continuing challenges facing drug research and development for Alzheimer’s is a vaccine. Swiss AC Immune has developed an Abeta-focused vaccine called ACI-24, which shown to be both effective and safe in pre-clinical models. As well as studying ACI-24 in Alzheimer’s patients, the company is investigating the candidate in Down syndrome patients who have a genetic predisposition to developing Alzheimer’s and are a more homogenous patient group. Believed to be caused by the build-up of plaques in the brain consisting of fibrillary amyloid beta (ABeta) peptides and neurofibrillary tangles of tau proteins, Alzheimer’s disease affects approximately 50 million people globally and is the leading cause of dementia. Despite its prevalence, academic researchers and the pharmaceutical industry have struggled to develop effective therapies against Alzheimer’s disease, with many drugs failing in late stage clinical trials. Research carried out between 2002 and 2012 concluded that the condition has a 99.6% trial failure rate.

Read More

Vaccine for Lassa Fever Set To Be Trialed

Technology Networks | October 25, 2019

There is currently no vaccine for the Lassa arenavirus, which causes Lassa fever. This hemorrhagic fever, endemic in West Africa, infects up to 300,000 people each year. Given the urgency of the situation, scientists in the Biology of Viral Emerging Infections Unit and the Viral Genomics and Vaccination Unit at the Institut Pasteur evaluated the efficacy of several vaccine candidates. Following their analyses, they identified one of these vaccines, based on the measles platform, as being the most effective to enter clinical testing in humans as soon as possible. This raises hopes in the fight against a disease that claims between 5,000 and 6,000 lives every year. Lassa fever, a hemorrhagic fever caused by the Lassa virus (LASV), is responsible for several thousands of deaths in endemic countries in West Africa every year. The natural reservoir of the virus is a peridomestic rodent that lives near or inside homes, so contacts between humans and the infected reservoir in villages are frequent (see our disease fact sheet). Humans are generally infected by ingesting or inhaling material contaminated with the animal's excreta (urine or feces). Early diagnosis of Lassa fever is difficult to establish because the first symptoms are non-specific (fever, vomiting and nausea), and there is currently no treatment. Vaccinating the populations concerned is therefore the most promising strategy to deal with recurrent outbreaks of Lassa fever. The World Health Organization (WHO) has included Lassa fever in its R&D Blueprint list of epidemic threats needing urgent R&D action. Frédéric Tangy, Head of the Institut Pasteur's Viral Genomics and Vaccination Unit, said in an interview: "When it comes to vaccines, all the easy work has already been done, and the more difficult work has still not been completed. Fundamental research is vital for the development of new solutions."

Read More

Lipid nanoparticles used to deliver RNA in vaccines

European Pharmaceutical Review | September 30, 2019

Researchers have developed a series of lipid nanoparticles, which encapsulate RNA, for effective and improved vaccine delivery. Researchers have developed a series of lipid nanoparticles to deliver RNA vaccines accurately, to ensure the therapy reaches the correct immune cells and produces sufficient amounts of the encoded protein. A team from the Massachusetts Institute of Technology (MIT), US conducted the research into the vaccine. They say it also behaves like an “adjuvant”, boosting the effectiveness of the treatment. Using mouse models, the researchers showed that the RNA vaccine is successful in inhibiting the growth of melanoma tumours. “One of the key discoveries of this paper is that you can build RNA delivery lipids that can also activate the immune system in important ways,” says Daniel Anderson, an associate professor at MIT and the senior author of the study. Anderson’s lab has previously developed lipid nanoparticles for delivering RNA and DNA for a variety of applications. These lipid particles form tiny droplets that protect the RNA molecules and carry them to their destinations.

Read More

Vaccines for Alzheimer’s: exploiting similarities with Down syndrome

Pharmaceutical Technology | September 20, 2019

One approach to overcome continuing challenges facing drug research and development for Alzheimer’s is a vaccine. Swiss AC Immune has developed an Abeta-focused vaccine called ACI-24, which shown to be both effective and safe in pre-clinical models. As well as studying ACI-24 in Alzheimer’s patients, the company is investigating the candidate in Down syndrome patients who have a genetic predisposition to developing Alzheimer’s and are a more homogenous patient group. Believed to be caused by the build-up of plaques in the brain consisting of fibrillary amyloid beta (ABeta) peptides and neurofibrillary tangles of tau proteins, Alzheimer’s disease affects approximately 50 million people globally and is the leading cause of dementia. Despite its prevalence, academic researchers and the pharmaceutical industry have struggled to develop effective therapies against Alzheimer’s disease, with many drugs failing in late stage clinical trials. Research carried out between 2002 and 2012 concluded that the condition has a 99.6% trial failure rate.

Read More

Events